Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARLS adjuvant pembrolizumab versus placebo after resection in early-stage NSCLC
NL-OMON60372Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoints: Disease-free survival in the PD-L1 strong positive subgroup and Disease-free survival in the overall population. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60372.